EGLN1 inhibition reverses angiogenesis impairment in hyperglycemia by activating autophagy.

ABSTRACT: Cardiovascular complications have emerged as the predominant cause of mortality in diabetes mellitus (DM), with diabetic cardiomyopathy (DCM) representing a critical clinical challenge due to its distinct pathogenesis independent of coronary artery disease or hypertension. DCM is characterized by left ventricular diastolic dysfunction, hypertrophy, and fibrosis, with impaired myocardial angiogenesis contributing to adverse cardiovascular outcomes. Despite this, targeted therapies for angiogenesis restoration in DCM remain elusive. Through bioinformatic analysis of public databases, we identified egl-9 family hypoxia inducible factor 1 (EGLN1) as a differentially expressed gene in both preclinical DCM models and clinical specimens. To validate its role, we established mice model of diabetes

SUBMITTER: Hu F 

PROVIDER: S-EPMC12521508 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature